Erasca (ERAS) Competitors $1.17 -0.02 (-1.68%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ERAS vs. IRON, TVTX, SDGR, IDYA, MESO, IMCR, INDV, CGON, VERA, and SPRYShould you be buying Erasca stock or one of its competitors? The main competitors of Erasca include Disc Medicine (IRON), Travere Therapeutics (TVTX), Schrödinger (SDGR), IDEAYA Biosciences (IDYA), Mesoblast (MESO), Immunocore (IMCR), Indivior (INDV), CG Oncology (CGON), Vera Therapeutics (VERA), and ARS Pharmaceuticals (SPRY). These companies are all part of the "pharmaceutical products" industry. Erasca vs. Disc Medicine Travere Therapeutics Schrödinger IDEAYA Biosciences Mesoblast Immunocore Indivior CG Oncology Vera Therapeutics ARS Pharmaceuticals Erasca (NASDAQ:ERAS) and Disc Medicine (NASDAQ:IRON) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk, community ranking and valuation. Do analysts recommend ERAS or IRON? Erasca presently has a consensus price target of $4.83, suggesting a potential upside of 306.16%. Disc Medicine has a consensus price target of $93.80, suggesting a potential upside of 127.06%. Given Erasca's higher possible upside, equities analysts clearly believe Erasca is more favorable than Disc Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Erasca 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Disc Medicine 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09 Does the MarketBeat Community believe in ERAS or IRON? Disc Medicine received 29 more outperform votes than Erasca when rated by MarketBeat users. Likewise, 86.57% of users gave Disc Medicine an outperform vote while only 74.36% of users gave Erasca an outperform vote. CompanyUnderperformOutperformErascaOutperform Votes2974.36% Underperform Votes1025.64% Disc MedicineOutperform Votes5886.57% Underperform Votes913.43% Is ERAS or IRON more profitable? Disc Medicine's return on equity of -25.24% beat Erasca's return on equity.Company Net Margins Return on Equity Return on Assets ErascaN/A -42.26% -34.97% Disc Medicine N/A -25.24%-23.96% Do institutionals & insiders hold more shares of ERAS or IRON? 67.8% of Erasca shares are held by institutional investors. Comparatively, 83.7% of Disc Medicine shares are held by institutional investors. 21.5% of Erasca shares are held by insiders. Comparatively, 4.2% of Disc Medicine shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media favor ERAS or IRON? In the previous week, Disc Medicine had 4 more articles in the media than Erasca. MarketBeat recorded 9 mentions for Disc Medicine and 5 mentions for Erasca. Erasca's average media sentiment score of 0.91 beat Disc Medicine's score of 0.76 indicating that Erasca is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Disc Medicine 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, ERAS or IRON? Erasca has a beta of 1.14, suggesting that its stock price is 14% more volatile than the S&P 500. Comparatively, Disc Medicine has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Which has better valuation & earnings, ERAS or IRON? Disc Medicine is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioErascaN/AN/A-$125.04M-$0.74-1.61Disc MedicineN/AN/A-$76.43M-$3.99-10.35 SummaryDisc Medicine beats Erasca on 10 of the 16 factors compared between the two stocks. Remove Ads Get Erasca News Delivered to You Automatically Sign up to receive the latest news and ratings for ERAS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ERAS vs. The Competition Export to ExcelMetricErascaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$337.09M$6.33B$5.33B$7.57BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-1.436.8121.7017.82Price / SalesN/A225.96377.7294.61Price / CashN/A65.6738.1534.64Price / Book0.575.866.464.00Net Income-$125.04M$141.86M$3.20B$247.23M7 Day Performance-0.42%4.38%2.77%1.44%1 Month Performance-17.36%-12.76%-8.60%-6.26%1 Year Performance-38.34%-11.13%10.40%0.59% Erasca Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ERASErasca3.2946 of 5 stars$1.17-1.7%$4.83+313.1%-40.5%$331.42MN/A-1.41120Short Interest ↓IRONDisc Medicine2.5495 of 5 stars$39.20-4.9%$93.80+139.3%+35.4%$1.36BN/A-9.8530High Trading VolumeTVTXTravere Therapeutics2.5417 of 5 stars$15.17+1.2%$31.46+107.4%+135.9%$1.35B$233.18M-3.70460Analyst ForecastPositive NewsGap UpSDGRSchrödinger2.318 of 5 stars$18.21+1.0%$32.29+77.3%+0.2%$1.33B$207.54M-7.78790Analyst ForecastInsider TradeNews CoverageIDYAIDEAYA Biosciences3.4293 of 5 stars$15.14+2.9%$53.58+253.9%-59.1%$1.33B$7M-4.5980Gap DownHigh Trading VolumeMESOMesoblast2.6457 of 5 stars$10.40-1.6%$18.00+73.1%+108.3%$1.32B$5.67M0.0080Positive NewsGap DownIMCRImmunocore2.183 of 5 stars$26.28-3.6%$65.18+148.0%-50.8%$1.31B$310.20M-27.66320Analyst ForecastNews CoverageGap UpINDVIndivior3.7612 of 5 stars$9.39+2.6%$15.00+59.7%-53.9%$1.29B$1.19B-26.831,164Short Interest ↓Positive NewsGap DownCGONCG Oncology1.2242 of 5 stars$16.92-1.6%$63.88+277.5%-46.6%$1.29B$1.14M-11.9261Analyst ForecastPositive NewsHigh Trading VolumeVERAVera Therapeutics2.886 of 5 stars$19.94-6.4%$64.67+224.3%-53.6%$1.27BN/A-7.6440Positive NewsHigh Trading VolumeSPRYARS Pharmaceuticals3.1694 of 5 stars$12.83+0.2%$31.00+141.6%+62.2%$1.26B$89.15M-25.1690Gap DownHigh Trading Volume Remove Ads Related Companies and Tools Related Companies Disc Medicine Alternatives Travere Therapeutics Alternatives Schrödinger Alternatives IDEAYA Biosciences Alternatives Mesoblast Alternatives Immunocore Alternatives Indivior Alternatives CG Oncology Alternatives Vera Therapeutics Alternatives ARS Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ERAS) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredIf Gold Is ‘Stalling,’ Why Are Banks Hoarding Billions In Secret?Prosperity was something every American family could build, protect, and pass down. Because that's what legacy...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Erasca, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Erasca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ERAS Stock Free ERAS Stock Alerts